Your browser doesn't support javascript.
Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review.
He, Feng; Luo, Qingqing; Lei, Ming; Fan, Lixin; Shao, Xinning; Hu, Kaiyuan; Qin, Shuguang; Yu, Na; Cao, Jie; Yang, Liuping.
  • He F; Guangzhou First People's Hospital, The Second Affiliated Hospital of South China University of Technology, Guangzhou, China.
  • Luo Q; Guangzhou First People's Hospital, The Second Affiliated Hospital of South China University of Technology, Guangzhou, China.
  • Lei M; Guangzhou Eighth people's hospital, Guangzhou Medical University, Guangzhou, 510060, China.
  • Fan L; Guangzhou Eighth people's hospital, Guangzhou Medical University, Guangzhou, 510060, China.
  • Shao X; Guangzhou Eighth people's hospital, Guangzhou Medical University, Guangzhou, 510060, China.
  • Hu K; Guangzhou Eighth people's hospital, Guangzhou Medical University, Guangzhou, 510060, China.
  • Qin S; Guangzhou First People's Hospital, The Second Affiliated Hospital of South China University of Technology, Guangzhou, China.
  • Yu N; Guangzhou First People's Hospital, The Second Affiliated Hospital of South China University of Technology, Guangzhou, China.
  • Cao J; Guangzhou First People's Hospital, The Second Affiliated Hospital of South China University of Technology, Guangzhou, China.
  • Yang L; Guangzhou Eighth people's hospital, Guangzhou Medical University, Guangzhou, 510060, China. gz8hylp@126.com.
Clin Rheumatol ; 39(9): 2803-2810, 2020 Sep.
Artículo en Inglés | MEDLINE | ID: covidwho-679748
ABSTRACT
COVID-19 has become a global concern. A large number of reports have explained the clinical characteristics and treatment strategies of COVID-19, but the characteristics and treatment of COVID-19 patient with systemic lupus erythematosus (SLE) are still unclear. Here, we report the clinical features and treatment of the first SLE patient with confirmed COVID-19 pneumonia. This was a 39-year-old woman, diagnosed with SLE 15 years ago, whose overall clinical characteristics (symptoms, laboratory tests, and chest CTs) were similar to those of the general COVID-19 patients. She continued to take the previous SLE drugs (doses of glucocorticoids, hydroxychloroquine, and immunosuppressive agents were not reduced) and was treated with strict antiviral and infection prevention treatment. After the first discharge, she got a recurrence of COVID-19 during her home isolation, and then returned to hospital and continued the previous therapy. Finally, this long-term immune suppressive patient's COVID-19 was successfully cured. The successful recovery of this case has significant reference value for the future treatment of COVID-19 patients with SLE. Key Points • COVID-19 patients with SLE is advocated to continue the medical treatment for SLE. • Hydroxychloroquine may have potential benefits for COVID-19 patients with SLE. • COVID-19 patients with SLE is prone to relapse, and multiple follow-ups are necessary.
Asunto(s)
Palabras clave

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Antivirales / Neumonía Viral / ARN Viral / Infecciones por Coronavirus / Antirreumáticos / Ritonavir / Lopinavir / Glucocorticoides / Hidroxicloroquina / Inmunosupresores Tipo de estudio: Reporte de caso / Estudios diagnósticos / Estudio pronóstico Tópicos: Covid persistente Límite: Adulto / Femenino / Humanos Idioma: Inglés Revista: Clin Rheumatol Año: 2020 Tipo del documento: Artículo País de afiliación: S10067-020-05230-0

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Antivirales / Neumonía Viral / ARN Viral / Infecciones por Coronavirus / Antirreumáticos / Ritonavir / Lopinavir / Glucocorticoides / Hidroxicloroquina / Inmunosupresores Tipo de estudio: Reporte de caso / Estudios diagnósticos / Estudio pronóstico Tópicos: Covid persistente Límite: Adulto / Femenino / Humanos Idioma: Inglés Revista: Clin Rheumatol Año: 2020 Tipo del documento: Artículo País de afiliación: S10067-020-05230-0